Form 4: Aytu BioPharma Executive Greg Pyszczymuka Reports Stock Transactions
SEC Form 4 Filing
Chief Commercial Officer Greg Pyszczymuka reports the vesting of restricted stock units into Aytu BioPharma common shares.
Summary
- On September 30, 2024, Greg Pyszczymuka, Chief Commercial Officer of Aytu BioPharma, reported the vesting of 209 restricted stock units (RSUs) into common shares.
- These RSUs, granted on March 31, 2022, vest quarterly from March 31, 2023, to March 31, 2025.
- Following the transaction, Pyszczymuka directly owns 23,185 common shares.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions, with neutral sentiment.
Industry Context
This is a standard SEC Form 4 filing, reflecting a company executive's stock transactions, which is a routine part of corporate governance and transparency.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a small increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| March 31, 2022 | Date the restricted stock units (RSUs) were granted. |
| March 31, 2023 | Start date for quarterly vesting of RSUs. |
| September 30, 2024 | Date of the reported transaction where RSUs vested into common shares. |
| March 31, 2025 | End date for quarterly vesting of RSUs. |
| October 01, 2024 | Date of signature for the Form 4 filing. |
Keywords
Aytu BioPharma, Greg Pyszczymuka, Form 4, Stock Transaction, Restricted Stock Units, AYTU, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.